Oral Wegovy approved

Weight-loss shots work by copying a gut hormone that tells the brain “you’ve had enough” and slows how fast food leaves the stomach. Semaglutide is the drug in Wegovy, and the United States Food and Drug Administration now lists both an injected version and an oral tablet version in the official label. (fda.gov) Getting that same drug into a pill has been unusually hard because stomach acid and digestive enzymes break peptide medicines apart like scissors cutting thread. Novo Nordisk’s oral semaglutide tablet uses an absorption helper so some of the drug can cross the stomach lining instead of being destroyed first. (fda.gov) The new tablet is not a casual “take it with breakfast” drug. The label says adults should take it once a day on an empty stomach with no more than 4 ounces of plain water and then wait at least 30 minutes before eating, drinking, or taking other oral medicines. (fda.gov) The tradeoff for avoiding a weekly injection is that the pill is dosed much higher. The approved tablets step up from 3 milligrams to 25 milligrams and then to 50 milligrams, while the familiar injected Wegovy doses are measured in much smaller weekly amounts because a shot bypasses the digestive tract. (fda.gov) Novo Nordisk has been getting ready for this for months. Its United States news archive says the company had already put Wegovy pills in a Super Bowl ad in February 2026, cut list prices on semaglutide medicines in February, and announced a multi-month Wegovy subscription program in March as it widened access. (novonordisk-us.com) The bigger surprise landed almost at the same time: a genetics study tied the drug’s uneven results to DNA differences in the people taking it. A Nature news report says researchers analyzed nearly 28,000 people and found variants linked both to stronger weight loss and to higher odds of gastrointestinal side effects such as nausea and vomiting. (nature.com) One of the clearest signals sat in the drug’s own lock. The underlying Nature paper says variants in GLP1R, the gene for the glucagon-like peptide-1 receptor that semaglutide targets, were associated with differences in weight loss response. (nature.com) Another signal showed up in GIPR, a related gut-hormone receptor gene. Nature’s accompanying analysis says that helps explain why some people lose much more weight than others on the same class of medicines and why others get more stomach problems before they ever see the full benefit. (nature.com, nature.com) Put those two pieces together and the next version of obesity treatment looks less like “one blockbuster drug for everyone” and more like matching the right person to the right format and dose. The pill gives doctors a new way to prescribe semaglutide, and the genetics work points toward a future where they may also predict who is most likely to respond well before the first prescription is written. (fda.gov, nature.com)